AR104326A1 - 5-SUBSTITUTED NUCLEOSID COMPOUNDS - Google Patents
5-SUBSTITUTED NUCLEOSID COMPOUNDSInfo
- Publication number
- AR104326A1 AR104326A1 ARP160101081A ARP160101081A AR104326A1 AR 104326 A1 AR104326 A1 AR 104326A1 AR P160101081 A ARP160101081 A AR P160101081A AR P160101081 A ARP160101081 A AR P160101081A AR 104326 A1 AR104326 A1 AR 104326A1
- Authority
- AR
- Argentina
- Prior art keywords
- cancer
- compounds
- hydrogen
- fluoro
- chlorine
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- VZQXUWKZDSEQRR-UHFFFAOYSA-N Nucleosid Natural products C12=NC(SC)=NC(NCC=C(C)C)=C2N=CN1C1OC(CO)C(O)C1O VZQXUWKZDSEQRR-UHFFFAOYSA-N 0.000 title 1
- 239000001257 hydrogen Substances 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 4
- 125000001153 fluoro group Chemical group F* 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- 206010005003 Bladder cancer Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 206010039491 Sarcoma Diseases 0.000 abstract 1
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000000460 chlorine Chemical group 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 208000006990 cholangiocarcinoma Diseases 0.000 abstract 1
- QPJDMGCKMHUXFD-UHFFFAOYSA-N cyanogen chloride Chemical compound ClC#N QPJDMGCKMHUXFD-UHFFFAOYSA-N 0.000 abstract 1
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 206010017758 gastric cancer Diseases 0.000 abstract 1
- 208000005017 glioblastoma Diseases 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 1
- 239000002777 nucleoside Substances 0.000 abstract 1
- -1 nucleoside compounds Chemical class 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Chemical class 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000011549 stomach cancer Diseases 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract 1
- 201000005112 urinary bladder cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Saccharide Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente solicitud se refiere a compuestos nucleósidos 5-sustituidos, composiciones farmacéuticas que comprenden los compuestos, y métodos de utilización de los compuestos para el tratamiento del cáncer, en particular los glioblastomas, melanoma, sarcomas, cáncer gástrico, cáncer de páncreas, colangiocarcinoma, cáncer de vejiga, cáncer de mama, cáncer de pulmón de células no pequeñas, leucemias, incluyendo leucemia mieloide aguda y los linfomas. Reivindicación 1: Un compuesto de la fórmula (1) donde: R¹ᵃ es hidrógeno, C₁₋₂ alquilo, C₃₋₆ cicloalcoxi, trifluorometil, ciano, cloro, o fluoro; R¹ᵇ es hidrógeno, cloro, o fluoro; R² es hidrógeno o C₁₋₃ alquilo; y R³ es hidrógeno, metil o amino; o una sal de la misma aceptable para uso farmacéutico.The present application relates to 5-substituted nucleoside compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer, in particular glioblastomas, melanoma, sarcomas, gastric cancer, pancreatic cancer, cholangiocarcinoma, Bladder cancer, breast cancer, non-small cell lung cancer, leukemia, including acute myeloid leukemia and lymphomas. Claim 1: A compound of the formula (1) wherein: R¹ᵃ is hydrogen, C₁₋₂ alkyl, C₃₋₆ cycloalkoxy, trifluoromethyl, cyano, chlorine, or fluoro; R¹ᵇ is hydrogen, chlorine, or fluoro; R² is hydrogen or C₁₋₃ alkyl; and R³ is hydrogen, methyl or amino; or a salt thereof acceptable for pharmaceutical use.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15382225 | 2015-05-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR104326A1 true AR104326A1 (en) | 2017-07-12 |
Family
ID=53177322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160101081A AR104326A1 (en) | 2015-05-04 | 2016-04-20 | 5-SUBSTITUTED NUCLEOSID COMPOUNDS |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US9840532B2 (en) |
| EP (1) | EP3292128A1 (en) |
| JP (2) | JP6181889B1 (en) |
| KR (1) | KR20170132871A (en) |
| CN (1) | CN107580602A (en) |
| AR (1) | AR104326A1 (en) |
| AU (1) | AU2016258485A1 (en) |
| BR (1) | BR112017020336A2 (en) |
| CA (1) | CA2981097A1 (en) |
| CL (1) | CL2017002637A1 (en) |
| CO (1) | CO2017010727A2 (en) |
| CR (1) | CR20170443A (en) |
| DO (1) | DOP2017000255A (en) |
| EA (1) | EA201792169A1 (en) |
| EC (1) | ECSP17072987A (en) |
| HK (1) | HK1244007A1 (en) |
| IL (1) | IL254409A0 (en) |
| MA (1) | MA42036A (en) |
| MX (1) | MX2017014001A (en) |
| PE (1) | PE20180231A1 (en) |
| PH (1) | PH12017502002A1 (en) |
| SG (1) | SG11201708345XA (en) |
| TN (1) | TN2017000459A1 (en) |
| TW (1) | TWI615400B (en) |
| WO (1) | WO2016178870A1 (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3262057B1 (en) * | 2015-02-24 | 2020-04-15 | Pfizer Inc | Substituted nucleoside derivatives useful as anticancer agents |
| JP7043080B2 (en) * | 2017-01-27 | 2022-03-29 | 国立大学法人 宮崎大学 | Efficacy judgment kit for cancer and efficacy judgment method for cancer |
| WO2018152501A1 (en) | 2017-02-20 | 2018-08-23 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| WO2018152548A1 (en) | 2017-02-20 | 2018-08-23 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| WO2018160855A1 (en) | 2017-03-01 | 2018-09-07 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| EP3665179B1 (en) | 2017-08-09 | 2021-06-09 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| JP7328218B2 (en) | 2017-10-26 | 2023-08-16 | プレリュード セラピューティクス，インコーポレイティド | Selective inhibitor of protein arginine methyltransferase 5 (PRMT5) |
| CU24621B1 (en) | 2017-12-13 | 2022-09-08 | Lupin Ltd | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPONENTS AS PRMT5 INHIBITORS |
| US10711007B2 (en) | 2018-03-14 | 2020-07-14 | Prelude Therapeutics Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) |
| DK3765461T3 (en) | 2018-03-14 | 2023-11-20 | Prelude Therapeutics Inc | SELECTIVE PROTEIN ARGININE METHYL TRANSFERASE 5 (PRMT5) INHIBITORS |
| JP7337539B2 (en) * | 2018-06-21 | 2023-09-04 | メディヴィル・アクチエボラーグ | Base-Modified Cytidine Nucleotides for Leukemia Therapy |
| WO2020033285A1 (en) * | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| US20220160713A1 (en) * | 2019-02-13 | 2022-05-26 | Prelude Therapeutics, Incorporated | Selective inhibitor of protein arginine methyltransferase 5 (prmt5) |
| WO2020206299A1 (en) | 2019-04-05 | 2020-10-08 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 |
| CR20220010A (en) | 2019-06-10 | 2022-05-13 | Lupin Ltd | PRMT5 INHIBITORS |
| US12414953B2 (en) | 2019-09-18 | 2025-09-16 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) |
| MX2022004917A (en) | 2019-10-22 | 2022-08-04 | Lupin Ltd | Pharmaceutical combination of prmt5 inhibitors. |
| US20230066014A1 (en) | 2019-12-03 | 2023-03-02 | Lupin Limited | Substituted nucleoside analogs as prmt5 inhibitors |
| GB202117230D0 (en) | 2021-11-29 | 2022-01-12 | Argonaut Therapeutics Ltd | Peptide vaccine |
| GB202203588D0 (en) | 2022-03-15 | 2022-04-27 | Argonaut Therapeutics Ltd | Cancer diagnostic |
| CN116211869B (en) * | 2022-12-07 | 2023-08-01 | 浙江省肿瘤医院 | Drug mixture containing DNA damage repair inhibitor, mixing method and use |
| WO2026008533A1 (en) | 2024-07-01 | 2026-01-08 | Janssen Pharmaceutica Nv | Prmt5 inhibitors for treating adenomas |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK1772002A3 (en) | 1999-08-27 | 2002-10-08 | Icn Pharmaceuticals | Nucleoside analog, method of change of cytokine secreting from a cell and method for inhibiting the growth of hyperproliferative cells |
| NZ544187A (en) * | 2005-12-15 | 2008-07-31 | Ind Res Ltd | Deazapurine analogs of 1'-aza-l-nucleosides |
| WO2011079236A1 (en) | 2009-12-22 | 2011-06-30 | The Ohio State University Research Foundation | Compositions and methods for cancer detection and treatment |
| US9416154B2 (en) * | 2011-07-13 | 2016-08-16 | Merck Sharp & Dohme Corp. | 5′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| US8906900B2 (en) | 2012-12-21 | 2014-12-09 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
| WO2014100716A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| US9745291B2 (en) | 2012-12-21 | 2017-08-29 | Epizyme, Inc. | PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof |
| HRP20182037T1 (en) | 2012-12-21 | 2019-02-08 | Epizyme, Inc. | PRMT5 INHIBITORS AND THEIR USE |
| US20150344457A1 (en) | 2012-12-21 | 2015-12-03 | Epizyme, Inc. | Methods of inhibiting prmt5 |
| WO2014100734A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| EP3262057B1 (en) * | 2015-02-24 | 2020-04-15 | Pfizer Inc | Substituted nucleoside derivatives useful as anticancer agents |
-
2016
- 2016-04-20 AR ARP160101081A patent/AR104326A1/en unknown
- 2016-04-22 TW TW105112724A patent/TWI615400B/en not_active IP Right Cessation
- 2016-04-27 HK HK18103599.9A patent/HK1244007A1/en unknown
- 2016-04-27 EA EA201792169A patent/EA201792169A1/en unknown
- 2016-04-27 EP EP16720676.2A patent/EP3292128A1/en not_active Withdrawn
- 2016-04-27 BR BR112017020336-7A patent/BR112017020336A2/en not_active Application Discontinuation
- 2016-04-27 PE PE2017002330A patent/PE20180231A1/en not_active Application Discontinuation
- 2016-04-27 MA MA042036A patent/MA42036A/en unknown
- 2016-04-27 JP JP2016575652A patent/JP6181889B1/en not_active Expired - Fee Related
- 2016-04-27 AU AU2016258485A patent/AU2016258485A1/en not_active Abandoned
- 2016-04-27 TN TNP/2017/000459A patent/TN2017000459A1/en unknown
- 2016-04-27 CR CR20170443A patent/CR20170443A/en unknown
- 2016-04-27 CA CA2981097A patent/CA2981097A1/en not_active Abandoned
- 2016-04-27 SG SG11201708345XA patent/SG11201708345XA/en unknown
- 2016-04-27 CN CN201680025080.3A patent/CN107580602A/en active Pending
- 2016-04-27 MX MX2017014001A patent/MX2017014001A/en unknown
- 2016-04-27 US US15/139,370 patent/US9840532B2/en not_active Expired - Fee Related
- 2016-04-27 KR KR1020177031713A patent/KR20170132871A/en not_active Withdrawn
- 2016-04-27 WO PCT/US2016/029475 patent/WO2016178870A1/en not_active Ceased
-
2017
- 2017-02-15 JP JP2017025494A patent/JP2017125029A/en active Pending
- 2017-09-11 IL IL254409A patent/IL254409A0/en unknown
- 2017-10-17 CL CL2017002637A patent/CL2017002637A1/en unknown
- 2017-10-20 CO CONC2017/0010727A patent/CO2017010727A2/en unknown
- 2017-10-30 DO DO2017000255A patent/DOP2017000255A/en unknown
- 2017-11-01 EC ECIEPI201772987A patent/ECSP17072987A/en unknown
- 2017-11-03 PH PH12017502002A patent/PH12017502002A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP17072987A (en) | 2018-02-28 |
| SG11201708345XA (en) | 2017-11-29 |
| TW201712022A (en) | 2017-04-01 |
| DOP2017000255A (en) | 2018-01-15 |
| PE20180231A1 (en) | 2018-01-31 |
| MA42036A (en) | 2018-03-14 |
| US9840532B2 (en) | 2017-12-12 |
| KR20170132871A (en) | 2017-12-04 |
| BR112017020336A2 (en) | 2019-05-14 |
| TWI615400B (en) | 2018-02-21 |
| MX2017014001A (en) | 2018-03-16 |
| JP2017125029A (en) | 2017-07-20 |
| IL254409A0 (en) | 2017-11-30 |
| TN2017000459A1 (en) | 2019-04-12 |
| JP2017525667A (en) | 2017-09-07 |
| PH12017502002A1 (en) | 2018-03-26 |
| JP6181889B1 (en) | 2017-08-16 |
| AU2016258485A1 (en) | 2017-10-12 |
| CO2017010727A2 (en) | 2018-01-31 |
| US20160326208A1 (en) | 2016-11-10 |
| CA2981097A1 (en) | 2016-11-10 |
| EP3292128A1 (en) | 2018-03-14 |
| WO2016178870A1 (en) | 2016-11-10 |
| CR20170443A (en) | 2017-11-07 |
| HK1244007A1 (en) | 2018-07-27 |
| EA201792169A1 (en) | 2018-03-30 |
| CN107580602A (en) | 2018-01-12 |
| CL2017002637A1 (en) | 2018-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR104326A1 (en) | 5-SUBSTITUTED NUCLEOSID COMPOUNDS | |
| CR20180547A (en) | PYRIDINES SUBSTITUTED WITH HETEROARYL AND METHODS OF USE | |
| MX2018003432A (en) | HETEROCICLICAL COMPOUNDS AND USES OF THE SAME. | |
| EA201791563A1 (en) | SUBSTITUTED NUCLEOSIDE DERIVATIVES, USEFUL AS AN AGENT AGAINST CANCER | |
| UY35641A (en) | SYNTHESIS PROCEDURE TO PREPARE MACROCYCLIC ANALOGS C1-HALICONDRINE B CHECK, AND USEFUL INTERMEDIARIES INCLUDING INTERMEDIARIES CONTAINING GROUPS? SO2- (p-TOLILO) | |
| CU20170164A7 (en) | N-TIEN (2,3-D) PYRIMIDINYL-D-PHENYLALANINE COMPOUNDS, METHOD FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| SG10201805628TA (en) | Deuterated heterocyclic compounds and their use as imaging agents | |
| CY1118478T1 (en) | AZAZIDAZOL OR DIAZANDAZOLI TYPE PRODUCTS FOR TREATMENT OF PAIN | |
| MX373711B (en) | Sulfamoylarylamides and their use as drugs for the treatment of hepatitis B. | |
| PH12015501934A1 (en) | New octahydro - pyrrolo [3,4-c] - pyrrole derivatives and analogs thereof as autotaxin inhibitors | |
| PH12017502334A1 (en) | Polycyclic amide derivative as cdk9 inhibitors | |
| CR20190566A (en) | QUINASA INHIBITORS AND USES OF THEM | |
| AR100431A1 (en) | PIRIDINE PLADIENOLIDE COMPOUNDS AND METHODS OF USE | |
| WO2013076315A3 (en) | Substituted n-(tetrazol-5-yl)- and n-(triazol-5-yl)arylcarboxamide compounds and their use as herbicides | |
| CR20180143A (en) | NEW BICYCLE COMPOUNDS AS DUAL INHIBITORS OF ATX / CA | |
| ECSP13012596A (en) | ELABORATION PROCESS FOR PIRIMIDINE DERIVATIVES | |
| EA201401189A1 (en) | SUBSTITUTED N- (TETRAZOL-5-IL) - AND N- (TRIAZOL-5-IL) ARILKARBOXAMIDE COMPOUNDS AND THEIR USE AS HERBICIDES | |
| MA38982A1 (en) | Novel octahydro-cyclobuta [1,2-c; 3,4-c '] dipyrrol-2-yl | |
| SV2016005351A (en) | DERIVATIVES OF INDANO AND INDOLINA AND THE USE OF THE SAME AS ACTIVATORS OF THE SOLUBLE CYCLING GUANILATE | |
| EA201890898A1 (en) | NEW CONNECTIONS AND CRYPTOPHICINE CONJUGATES, THEIR RECOVERY AND THEIR THERAPEUTIC APPLICATION | |
| SA518390920B1 (en) | Novel annelated phenoxyacetamides | |
| PH12018500377A1 (en) | Novel annelated benzamides | |
| UY36416A (en) | 1- [2- (AMINOMETIL) BENCIL] -2-THIOXO-1,2,3,5-TETRAHYDRO-4H-PIRROLO [3,2-D] PYRIMIDIN-4-WAVES AS INHIBITORS OF MYELOPEROXIDASE | |
| CL2020002588A1 (en) | Indole-derived compounds, compositions containing them, useful in the treatment of infestation by helminths, preferably trematodes, in mammals. (Divisional Application No. 03258-2016) | |
| MX2018016290A (en) | Anti-greying agent. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |